Total Payments
$85,602
2024 Payments
$3,022
Companies
15
Transactions
200
Medicare Patients
9,062
Medicare Billing
$1.5M
Payment Breakdown by Category
Other$75,475 (88.2%)
Food & Beverage$6,158 (7.2%)
Travel$3,438 (4.0%)
Consulting$500.00 (0.6%)
Education$31.39 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $72,475 | 63 | 84.7% |
| Food and Beverage | $6,158 | 118 | 7.2% |
| Travel and Lodging | $3,438 | 12 | 4.0% |
| Honoraria | $3,000 | 2 | 3.5% |
| Consulting Fee | $500.00 | 1 | 0.6% |
| Education | $31.39 | 4 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Allergan, Inc. | $42,610 | 78 | $0 (2021) |
| Theravance Biopharma, Inc. | $22,369 | 28 | $0 (2018) |
| ABBVIE INC. | $11,925 | 49 | $0 (2024) |
| Cumberland Pharmaceuticals, Inc. | $4,138 | 5 | $0 (2019) |
| The Medicines Company | $3,518 | 17 | $0 (2017) |
| Abbott Laboratories | $568.46 | 4 | $0 (2018) |
| Merck Sharp & Dohme LLC | $157.85 | 10 | $0 (2024) |
| Daiichi Sankyo Inc. | $123.64 | 2 | $0 (2017) |
| AIMMUNE THERAPEUTICS, INC. | $102.47 | 1 | $0 (2024) |
| TETRAPHASE PHARMACEUTICALS, INC. | $22.97 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,022 | 24 | ABBVIE INC. ($2,887) |
| 2023 | $3,337 | 15 | AbbVie Inc. ($3,337) |
| 2022 | $2,785 | 7 | ABBVIE INC. ($2,785) |
| 2021 | $3,229 | 8 | AbbVie Inc. ($2,917) |
| 2020 | $6,116 | 20 | Allergan, Inc. ($6,093) |
| 2019 | $12,386 | 18 | Allergan Inc. ($8,248) |
| 2018 | $21,669 | 36 | Allergan Inc. ($14,738) |
| 2017 | $33,058 | 72 | Theravance Biopharma Inc. ($16,050) |
All Payment Transactions
200 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/22/2024 | ABBVIE INC. | TEFLARO (Drug) | Food and Beverage | In-kind items and services | $18.93 | General |
| Category: ANTI-INFECTIVE | ||||||
| 11/21/2024 | ABBVIE INC. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $18.47 | General |
| Category: ANTI-INFECTIVE | ||||||
| 11/19/2024 | ABBVIE INC. | DALVANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $675.00 | General |
| Category: ANTI-INFECTIVE | ||||||
| 11/06/2024 | ABBVIE INC. | TEFLARO (Drug) | Food and Beverage | In-kind items and services | $18.68 | General |
| Category: ANTI-INFECTIVE | ||||||
| 09/26/2024 | AIMMUNE THERAPEUTICS, INC. | ZENPEP (Drug) | Food and Beverage | In-kind items and services | $102.47 | General |
| Category: ENDOCRINE PANCREATIC INSUFFICIENCY | ||||||
| 09/25/2024 | ABBVIE INC. | AVYCAZ (Drug), TEFLARO, DALVANCE | Food and Beverage | In-kind items and services | $18.67 | General |
| Category: ANTI-INFECTIVE | ||||||
| 09/16/2024 | ABBVIE INC. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $18.58 | General |
| Category: ANTI-INFECTIVE | ||||||
| 09/06/2024 | ABBVIE INC. | TEFLARO (Drug) | Food and Beverage | In-kind items and services | $18.82 | General |
| Category: ANTI-INFECTIVE | ||||||
| 08/22/2024 | Merck Sharp & Dohme LLC | DIFICID (Drug), ZERBAXA | Food and Beverage | In-kind items and services | $15.16 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 08/13/2024 | ABBVIE INC. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $7.93 | General |
| Category: ANTI-INFECTIVE | ||||||
| 08/10/2024 | ABBVIE INC. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $17.21 | General |
| Category: ANTI-INFECTIVE | ||||||
| 07/31/2024 | Merck Sharp & Dohme LLC | DIFICID (Drug), RECARBRIO, ZERBAXA | Food and Beverage | In-kind items and services | $17.63 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 07/26/2024 | ABBVIE INC. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $17.55 | General |
| Category: ANTI-INFECTIVE | ||||||
| 07/18/2024 | ABBVIE INC. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $17.67 | General |
| Category: ANTI-INFECTIVE | ||||||
| 07/15/2024 | ABBVIE INC. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $17.75 | General |
| Category: ANTI-INFECTIVE | ||||||
| 06/26/2024 | ABBVIE INC. | TEFLARO (Drug) | Food and Beverage | In-kind items and services | $17.77 | General |
| Category: ANTI-INFECTIVE | ||||||
| 05/09/2024 | ABBVIE INC. | TEFLARO (Drug) | Food and Beverage | In-kind items and services | $17.17 | General |
| Category: ANTI-INFECTIVE | ||||||
| 05/08/2024 | ABBVIE INC. | TEFLARO (Drug) | Food and Beverage | In-kind items and services | $17.66 | General |
| Category: ANTI-INFECTIVE | ||||||
| 04/19/2024 | ABBVIE INC. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $17.82 | General |
| Category: ANTI-INFECTIVE | ||||||
| 03/28/2024 | ABBVIE INC. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $18.00 | General |
| Category: ANTI-INFECTIVE | ||||||
| 03/19/2024 | ABBVIE INC. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $17.93 | General |
| Category: ANTI-INFECTIVE | ||||||
| 02/27/2024 | ABBVIE INC. | AVYCAZ (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,875.00 | General |
| Category: ANTI-INFECTIVE | ||||||
| 02/08/2024 | ABBVIE INC. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $22.89 | General |
| Category: ANTI-INFECTIVE | ||||||
| 01/31/2024 | ABBVIE INC. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $17.25 | General |
| Category: ANTI-INFECTIVE | ||||||
| 12/13/2023 | AbbVie Inc. | TEFLARO (Drug) | Food and Beverage | In-kind items and services | $18.00 | General |
| Category: ANTI-INFECTIVE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 2,277 | 4,652 | $820,860 | $384,452 |
| 2022 | 5 | 2,238 | 4,205 | $743,900 | $327,071 |
| 2021 | 5 | 2,317 | 4,766 | $822,340 | $383,046 |
| 2020 | 6 | 2,230 | 4,859 | $868,325 | $407,494 |
Total Patients
9,062
Total Services
18,482
Medicare Billing
$1.5M
Procedure Codes
24
All Medicare Procedures & Services
24 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 672 | 2,739 | $328,680 | $180,250 | 54.8% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 597 | 801 | $176,220 | $79,353 | 45.0% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 650 | 725 | $217,500 | $78,467 | 36.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 191 | 200 | $68,000 | $28,906 | 42.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 65 | 69 | $13,800 | $7,482 | 54.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 73 | 88 | $10,560 | $6,729 | 63.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 14 | 14 | $4,900 | $2,602 | 53.1% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 15 | 16 | $1,200 | $661.60 | 55.1% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 726 | 2,420 | $290,400 | $144,866 | 49.9% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 698 | 780 | $234,000 | $87,960 | 37.6% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 596 | 747 | $164,340 | $64,061 | 39.0% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 110 | 110 | $37,400 | $18,573 | 49.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 108 | 148 | $17,760 | $11,611 | 65.4% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 771 | 2,944 | $353,280 | $182,562 | 51.7% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 570 | 670 | $201,000 | $78,264 | 38.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 621 | 757 | $166,540 | $67,375 | 40.5% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 244 | 246 | $83,640 | $42,847 | 51.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 111 | 149 | $17,880 | $11,999 | 67.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 707 | 2,647 | $317,640 | $166,653 | 52.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 654 | 1,252 | $275,440 | $115,717 | 42.0% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 556 | 635 | $182,040 | $75,885 | 41.7% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 248 | 253 | $86,095 | $45,576 | 52.9% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 36 | 38 | $4,560 | $2,507 | 55.0% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2020 | 29 | 34 | $2,550 | $1,156 | 45.3% |
About Dr. Paras Udani, DO
Dr. Paras Udani, DO is a Infectious Disease healthcare provider based in Pomona, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/07/2008. The National Provider Identifier (NPI) number assigned to this provider is 1801059183.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Paras Udani, DO has received a total of $85,602 in payments from pharmaceutical and medical device companies, with $3,022 received in 2024. These payments were reported across 200 transactions from 15 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($72,475).
As a Medicare-enrolled provider, Udani has provided services to 9,062 Medicare beneficiaries, totaling 18,482 services with total Medicare billing of $1.5M. Data is available for 4 years (2020–2023), covering 24 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Pomona, NJ
- Active Since 07/07/2008
- Last Updated 12/16/2019
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1801059183
Products in Payments
- AVYCAZ (Drug) $46,373
- VIBATIV (Drug) $22,369
- TEFLARO (Drug) $5,899
- Vibativ (Drug) $4,138
- ORBACTIV (Drug) $3,302
- DALVANCE (Drug) $2,264
- Supera peripheral stent system (Device) $568.46
- MINOCIN IV (Drug) $208.74
- Savaysa (Drug) $123.64
- ZERBAXA (Drug) $107.97
- ZENPEP (Drug) $102.47
- DIFICID (Drug) $32.79
- XERAVA (Drug) $22.97
- Primatrix (Device) $19.59
- SIVEXTRO (Drug) $17.09
- Vabomere (Drug) $11.95
- TRIUMEQ (Drug) $11.76
- Cresemba (Drug) $11.00
- KENGREAL (Drug) $7.17
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Pomona
Dr. Manish Trivedi, M.d, M.D
Infectious Disease — Payments: $72,933
Infectious Disease $72,933
John Mourani, Md, MD
Infectious Disease — Payments: $15,916
Infectious Disease $15,916
Dr. Kerry Gott, M.d, M.D
Infectious Disease — Payments: $3,092
Infectious Disease $3,092
Vinod Dhawan, Md, MD
Infectious Disease — Payments: $268.59
Infectious Disease $268.59
Daniel Gluckstein, M.d, M.D
Infectious Disease — Payments: $264.56
Infectious Disease $264.56
Ms. Irene Bakman, Md, MD
Infectious Disease — Payments: $211.09
Infectious Disease $211.09